Current partner codePEPTIDESDE
NCT07413913·Phase 1·INTERVENTIONAL

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

Status

Completed

Phase

Phase 1

Enrollment

56

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.

Interventions

Treatment arms and agents.

COMBINATION_PRODUCT

Survodutide formulation A

Pre-filled syringe

COMBINATION_PRODUCT

Survodutide formulation B2

Pre-filled pen

Timeline

From registration to results.

  1. First posted

    Feb 17, 2026

  2. Study start

    Mar 3, 2026

  3. Primary completion

    May 28, 2026

  4. Study completion

    Jun 11, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Jun 15, 2026

Outcomes

What the study measures.

Primary outcomes

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Time frame · Up to Day 22

Maximum measured concentration of the analyte in plasma (Cmax)

Time frame · Up to Day 22

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Time frame · Up to Day 22

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
55 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: 1. Male or female trial participant who is healthy or otherwise healthy with overweight/obesity according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests 2. Age of 18 to 55 years (inclusive) 3. Body mass index (BMI) of 22.0 to 39.9 kg/m2 (inclusive) 4. Signed and dated written informed consent in accordance with international council for harmonisation-good clinical practice (ICH-GCP) and local legislation prior to admission to the trial Further inclusion criteria apply. Exclusion Criteria: 1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator 2. Repeated measurement of systolic BP outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic BP outside the range of 50 to 90 mmHg, or PR outside the range of 45 to 90 beats per minute (bpm) 3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance 4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.

Study locations

1 registered sites.

Germany. Showing up to 24 locations stored in the fast local snapshot.

Humanpharmakologisches Zentrum Biberach

Biberach, Germany

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Survodutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.